Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hollis-Eden Pharmaceuticals has said that the US government has canceled a contract for its acute radiation syndrome drug Neumune because the Department of Health & Human Services found it technically unacceptable.
Subscribe to our email newsletter
The Department of Health & Human Services (HHS) said the product was no longer in the competitive range for the Request for Proposal (RFP).
Hollis-Eden Pharmaceuticals said it is surprised by this decision. In June 2006, HHS informed the company that its proposal for Neumune was within the competitive range. According to Hollis-Eden, since that time, HHS has not requested any additional safety or efficacy data on Neumune that had not previously been provided.
“This decision by HHS to exclude our proposal and cancel the RFP is shocking and difficult to understand,” stated Richard Hollis, chairman and CEO of Hollis-Eden.
“Neumune is the only agent ever to have shown the ability to reduce mortality from ARS in primates when administered as a single agent hours after radiation exposure without supportive care.”